Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

Cobepa Makes Growth Investment in Reaction Biology

March 16, 2022

Healthcare Services

Cobepa S.A. completed a growth investment in Reaction Biology to support expansion of the CRO's drug discovery capabilities and global footprint. The transaction includes financing from Golub Capital and coincides with the appointment of John H. Johnson as Reaction Biology's CEO.

Cobepa Acquires Majority Stake in Itineris

June 23, 2025

Software

Cobepa has signed an agreement to acquire a majority stake in Itineris, a Ghent-based provider of customer information systems and utility software. Existing institutional investors PMV, Gimv, Smartfin and SFPIM will exit, while founder and CEO Edgard Vermeersch remains the largest non-institutional shareholder; the investment is intended to accelerate growth, expand Itineris' global footprint, and strengthen its software capabilities for water and energy utilities.

GHO Capital and Ampersand Acquire Avid Bioservices for $1.1 Billion

November 7, 2024

Biotechnology

GHO Capital Partners and Ampersand Capital Partners have completed the acquisition of Avid Bioservices, a dedicated biologics CDMO, in an all-cash transaction valued at approximately $1.1 billion. The transaction takes Avid private (shareholders received $12.50 per share) and positions the company for capability expansion, geographic reach and accelerated growth under the new PE ownership.

Keensight Capital Acquires Majority Stake in Biovian

May 23, 2018

Biotechnology

Keensight Capital has acquired a majority stake in Biovian, a Finnish contract development and manufacturing organization (CDMO) for biopharmaceuticals, alongside the company's founders, managers and Edmond de Rothschild Equity Strategies (ERES) funds. Biovian, founded in 2003 and based in Finland with ~70 employees, provides end-to-end GMP manufacturing, development and analytical services for biologics, gene therapies and vaccines; Keensight will support scaling the business to become a leading European biologics CDMO.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.